2026 · 1st Quarter (Jan 1 - Mar 31)

PRIME THERAPEUTICS

Filed by PRIME THERAPEUTICS.

Open official filing

Source-reported fields

Filing overview

Type: 1st Quarter - Report
Posted: Apr 20, 2026
Income: Not reported
Expenses: $120,000.00
Registrant: PRIME THERAPEUTICS
Client: PRIME THERAPEUTICS
Filing UUID: 47f611ac-5c9a-45df-b977-cba5251feee7
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822, Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act -provisions related to interchangeability of biosimilars Department of Labors Notice of Proposed Rulemaking, Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (RIN 1210-AB37).

Literal federal measure citations: H.R. 7148, S. 2355, S. 3822, S. 1954, HR 5526

MMM · Medicare/Medicaid

H.R. 8143 Ensuring Access to Lower Cost Medicines for Seniors Act of 2026 provisions related to formulary placement of certain drugs. H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices H.R. 1227, Alternatives to PAIN Act requirements related to formulary Tierring and prior authorization in Medicare Part D for non-opioid pain medications.

Literal federal measure citations: H.R. 8143, H.R. 7148, H.R. 1227

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.